Swiss pharma giant Roche announced a partnership with Shape Therapeutics valued at more than $3 billion that will attempt to harness the Seattle-based company’s RNA editing platform to take on neurodegenerative diseases as well as others.
Three pharmaceutical and biotechnology companies announced the recent success of their respective funding rounds to support future efforts.
Shape Therapeutics generated $112 million from a recent Series B financing round the Seattle biotechnology firm co-led with Decheng Capital and Breton Capital.
Money on the Move: June 30 – July 6Biology, Business, CAR-T Therapy, Clinical Trials, CRISPR, Financing, Financing, Hereditary Transthyretin Amyloidosis (hATTR), Initial Public Offering (IPO), Nasdaq, Neuromodulation, Pulmonary Arterial Hypertension, R&D, Series A, Series B, Series C Financing, Shares
The IPO train continues to barrel down the tracks as more life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers.
The first half of 2021 saw a flurry of IPOs as multiple companies make the move to become publicly traded.
ObvioHealth Raises $31 Million, Adds Two Strategic Partners to Bolster Capabilities and Drive Growth Globally NEW YORK, July 1, 2021 /PRNewswire/ — ObvioHealth, a global Virtual Research Organization (VRO), announces it […]
Doceree Inc., the first global network of physician-only platforms for programmatic marketing, raised a pre-Series A funding for an undisclosed amount led by existing and new investors.
In a flurry of activity, multiple biopharma companies made their first appearance on the Nasdaq Stock Exchange on June 25, raising hundreds of millions of dollars to advance the development of next-generation therapeutics and scale their businesses.
Jerusalem-based SpliSense, which focuses on cystic fibrosis and other genetic pulmonary diseases, closed on a $28.5 million Series B financing round. Participating in the round were OrbiMed, Israel Biotech Fund, Integra Holdings and the Cystic Fibrosis Foundation.
2021 is shaping up to be another banner year for biotech companies. According to BioSpace, funds appear to be in near-endless supply as companies advance next-gen technologies and therapeutics for the health of all. BioSpace reviews a few raking in cash for their programs.